Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. Its products include the RetinalGeniX Imaging System, a diabetic non-mydriatic mass retinal imaging and screening device; and RetinalCam, a real-time in-home retinal monitoring, imaging, and physician alert system. The company was incorporated in 2017 and is headquartered in Petaluma, California. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Buy
Sell